This report aims to determine the permitted daily exposure (PDE) of flutamide, an androgen receptor blocker, as directed by guideline EMA/CHMP/CVPM/SWP/169430/2012 that came into effect on June 2015. A literature review was conducted to identify toxicity studies of flutamide. Hazards and sensitive endpoints were determined. Based on the no adverse effect levels (NOAELs) and lowest observed adverse effect levels (LOAELs) reported from both reproductive, developmental, and 28-day toxicity studies the PDE was calculated. Most of the toxicity studies converge toward a NOAEL of 1 mg/kg/d that translates to a PDE of 0.1 mg/d. However, taking into consideration the worst case scenarios for additional safety a PDE of 0.025 mg/d (25 lg/d) was calculated based on a reported NOAEL of 0.25 mg/kg/d. A PDE of 0.05 mg/d (50 lg/d) was also calculated from reproductive/developmental toxicity studies, which is in close agreement with the PDE from the 28-day toxicity studies. Considering the lowest PDE of 0.025 mg/d, residual flutamide at this dose is unlikely to pose any risk to humans. Nonmonotonic dose response (NMDR) effects of flutamide were not supported by literature. Oral route of administration was considered.
Effective June 2015 the European Medicines Agency (EMEA) requires that pharmaceutical companies should have the permitted daily exposure (PDE) reports, in accordance with Guideline EMA/CHMP/CVPM/SWP/169430/2012 (EMEA, 2014) . The PDE represents a substance-specific dose that is unlikely to cause an adverse effect if an individual is exposed at or below this dose every day for a lifetime. PDEs are set to provide a scientifically sound maximum allowable carry over limit of an active pharmaceutical ingredient (API) in drug A to a next batch (drug B) such that no adverse health effects are likely to be observed if a person takes drug B (that contains traces of API A) for life (EMEA, 2014) . These values are primarily used for cleaning validation purposes and are based on toxicology. In this article, the PDE for flutamide is calculated based on an extensive literature review and following the guidelines set by EMEA in calculating the PDE value.
Flutamide belongs to a class of compounds called androgen receptor(AR) blockers that competitively inhibit the natural ligands of the AR. AR blockers are used for treatment of patients with advanced/metastatic prostate cancer (where suppression of testosterone effect is indicated) usually in combination with other drugs. They are relatively potent antagonists but have limited efficacy when used alone as they increase luteinizing hormone (LH) secretion that results in increased testosterone concentrations (Anderson, 2003; Klotz, 2008; Ricci et al., 2014; Snyder, 2008) . AR blockers are thus often given in combination with Gonatotropin Releasing Hormone agonists to block potential deleterious effects resulting from transient increases in gonadotropins and testosterone. Flutamide has also been used effectively to treat hirsutism in women, but the association with hepatotoxicity argues against its routine use for this cosmetic purpose (Anderson, 2003; Klotz, 2008; Levy and Emer, 2013; Ricci et al., 2014; Snyder, 2008; Somani and Turvy, 2014) .
As an AR blocker flutamide is intrinsically an endocrine disrupting compound (EDC). EDCs are an emerging public health concern, as more data become available about their potential harmful effects on humans. They are so-named because of their ability to disrupt endogenous hormone activity, in particular steroid, estrogen, and androgen activity. It is well-known that in high doses, these compounds can cause morphological and functional effects in every system in the body that is regulated by hormones, including the nervous, immune, reproductive, and urogenital systems. High doses can also cause infertility and abnormal prenatal and childhood development as well (Gore, 2008; Kortenkamp, 2007; Ma, 2009; Pflieger-Bruss et al., 2004) .
In general, toxicity by EDCs is complicated since it involves the endocrine system, and any effect on estrogen or ARs affects not only the direct downstream gene expression but may affect the endocrine system and specifically the hypothalamicpituitary axis. For example, when the AR is blocked by flutamide, it affects the reproductive tract, but also alters the reproductive function at the level of the hypothalamic-pituitary axis. In this case LH is increased leading to increased testosterone or estrogen levels (Gore, 2008; Kortenkamp, 2007; Ma, 2009; Pflieger-Bruss et al., 2004; Vandenberg et al., 2012) .
Due to these complex and deleterious effects of AR antagonists the PDE of flutamide was chosen to be determined. The calculated value would constitute an important reference especially for pharmaceutical companies that need to comply with the new EMEA directive, and ensure the safety of human patients when exposed to residual active substances via medicinal products.
According to the directive, determination of a PDE involves (1) hazard identification by reviewing all relevant data, (2) identification of "critical effects", (3) determination of the no observed adverse effect level (NOAEL-defined as the highest tested dose at which no "critical" effect is observed) of the findings that are considered to be critical effects, and (4) use of several adjustment factors to account for various uncertainties (EMEA, 2014) .
Hazard identification relates to the ability of a substance to produce adverse effects, and its identification requires review of available animal and human data arising from nonclinical pharmacodynamic data, repeat-dose toxicity studies, carcinogenicity studies, in vitro and in vivo genotoxicity studies, reproductive and developmental toxicity studies as well as clinical data (therapeutic and adverse effects). Subsequently, the critical effects include the most sensitive indicator of an adverse effect seen in non-clinical toxicity studies. A critical effect would also include any clinical therapeutic and adverse effect, if applicable (EMEA, 2014) .
For all critical effects identified, a NOAEL is then established, if it has not already been identified in the literature. If many NOAELs are established the lowest dose is used for calculation of the PDE value. If no NOAEL is obtained, the lowest observed adverse effect level (LOAEL) may be used (EMEA, 2014) .
Based on these guidelines a review of the relevant flutamide literature was performed, and following the above guidelines a PDE was determined.
MATERIALS AND METHODS
PDE was calculated in accordance with the methodology described in EMA/CHMP/CVPM/SWP/169430/2012 Guideline on "Setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities" (EMEA, 2014) with reference to VICH GL 18 guideline "VICH GL 18 residual solvents in new veterinary medicinal products, active substances and excipients" (CVPM, 2010) .
PDEs are derived preferably from a NOAEL, or in the absence of NOAEL, a LOAEL, derived from relevant animal studies. PDE is thus calculated as:
where F1-F5 are modifying factors to relate the data used to human data and the weight adjustment assumes adult human weight of either sex. A detailed analysis of the F factors is shown in Table 1 . The weight adjustment is set by the EMEA directive to 50 kg for PDE determination. The F1 factor accounts for extrapolation between species taking into account comparative surface area, with F1 value being 5 for rat to human extrapolation since data obtained in this study were from rats. F2 is a factor to account for variability between individuals, and a factor of 10 is applied. F3 is a factor to account for toxicity studies of short term exposure, with F3 ¼ 1 for developmental toxicity studies where flutamide was given between gestational day (GD) 8 and 15 when organogenesis in rats occur (full organogenesis considered), and F3 ¼ 10 for 28-day toxicity studies which are considered shorter studies. F4 is a factor used to account for toxicity. In this case, F4 ¼ 1 was used since no severe toxicity was observed with flutamide administration in any of the studies examined. Finally F5 is a factor to account for use of NOAEL or LOAEL. If a NOAEL is used in the calculation a factor or 1 is applied, and if a LOAEL is used a factor of 10 is applied. For PDE determination of flutamide NOAELs from a number of published studies were considered covering mostly 28-day toxicity studies and developmental/reproductive studies. NOAELs from these studies were evaluated based on protocol followed, completeness of the study and adequate relevant data reporting to select the most appropriate value of the reported NOAELs for PDE determination.
RESULTS

AR Antagonistic Effect of Flutamide
AR agonistic or antagonistic effects are best determined by specific assays set by the Organization for Economic Co-operation and Development (OECD). The Hershberger assay proposed by OECD is an in vivo short-term screening test that evaluates the ability of a chemical to elicit biological activities consistent with androgen agonists or antagonists. It is based on the changes in weight of five androgen-dependent tissues in the castrateperipubertal male rat: the ventral prostate, seminal vesicle (plus fluids and coagulating glands), levator ani plus bulbocavernosus (LABC) muscle, paired Cowper's glands and the glans penis (OECD, 2009) .
Using the Hershberger assay Kang et al. (2004) showed in castrated rats (7 weeks of age), that subcutaneous testosterone (0.4 mg/kg) replacement for 10 days increases accessory organ weights while LH levels decrease in a dose dependent manner. Flutamide administered by oral gavage daily significantly inhibited the testosterone-induced regrowth of seminal vesicles, ventral prostate, and LABC muscles at 1 mg/kg/d and above (absolute weight in mg; seminal vesicles Treated (T): 279.5 6 48.3 vs Control (C): 484.3 6 59.2, ventral prostate T: 88.4 6 25.9 vs C: 153.7 6 28.5, LABC T: 410.5 6 51.8 vs C: 618.6 6 41.2, all p < .05 vs controls), and Cowper's glands and glans penis at 5 mg/kg/d and above (absolute weight in mg T: 23.8 6 2.6 vs C: 39.3 6 7.1, p < .05).
Using a 5-day Hershberger assay Yamada et al. (2000) using rats 11 weeks of age (n ¼ 6 per group dosed daily by oral gavage with flutamide dissolved in 0.5% carboxymethylcellulose at 0, 0.15, 0.6, 2.5, and 10 mg/kg for 5 days) showed similar effects of flutamide. However, the concentrations where flutamide produced significant decreases in weights of the seminal vesicles and the LABC muscles (>0.6 mg/kg/d) and ventral prostate (>2.5 mg/kg/d), and an increase in serum LH levels (>2.5 mg/kg/d) were different.
The aforementioned toxicity studies as well as others (Adamsson et al., 2008; Okahara et al., 2000) are short in duration (5-10 days) and merely determine the antiandrogenic effect of flutamide. No indication of LOAEL or NOAEL is given, or hazards and critical effects identified.
28-Day Repeat Dose Toxicity Studies
The Enhanced OECD protocol 407, is a 28-day toxicity study incorporating the Hershberger assay and additional endpoints in noncastrated rodents. Accordingly, more light on the NOAEL of flutamide is shed from these 28-day repeat dose toxicity studies in male rats. Most of the studies described below follow the enhanced OECD 407 protocol (OECD, 2008) , and use flutamide doses in the range from 0.04 to 150 mg/kg/d. Kunimatsu et al. (2004) and Freyberger et al. (2003) used flutamide doses of 0, 0.1, 1, 10, and 100 mg/kg on 7-week-old rats. Specifically, in the Kunimatsu study, two parallel studies (A, B) for each dose were conducted, using 5 animals per group dosed by oral gavage daily at 0, 1, 10, and 100 mg/kg body weight (bw) for 28-30 days. Vehicle was 2.0% (w/v) Cremophor EL. Initial bw (grams) of the animals were not statistically different between groups (weight in grams; (C): 251.7 6 8.5 (A) and 250.5 6 8.0 (B), 1 mg/kg: 258.7 6 9.6 (A) and 252.5 6 12.6 (B), 10 mg/kg: 253.5 6 10.7 (A) and 253.8 6 7.6 (B), 100 mg/kg: 250.4 6 7.7 (A), and 253.6 6 9.3 (B); p > .05). Terminal bws were not statistically different between groups either (weight in gram; C: 393.8 6 28.7 (A) and 369.9 6 30.8 (B), 1 mg/kg: 404.1 6 37.5 (A) and 392.1 6 26.5 (B), 10 mg/kg: 381.1 6 46.5 (A) and 379.5 6 14.3 (B), 100 mg/kg: 350.4 6 17.1 (A) and 372.7 6 29.4 (B); p > .05). In the Freyberger study, 10 animals per group were used, and dosed by oral gavage daily at 0, 0.1, 10, or 100 mg/kg bw for 28 days. Terminal bws (in grams) were 339 6 21 for control, 315 6 32, 326 6 36, and 298 6 20 for the 0.1, 10, and 100 mg/kg dose groups, respectively. No differences in the bw were observed between the groups except for the 100 mg/ kg dose group which was statistically significant from the rest.
In both studies the 100 mg/kg dose, which represents the mean therapeutic dose, had statistically significant effect on androgen dependent organs and epididymis. In the Freyberger study, relative organ weights were (mg/100g): epididymis: treated (T): 120 6 30 versus control (C): 191 6 1.7, ventral prostate: T: 31 6 15 versus C: 123 6 20, seminal vesicles plus dorsolateral prostate: T: 102 6 17 versus C: 470 6 73 (all p < .05 vs control). In the Kunimatsu study absolute weight (g) for epididymis in the 2 studies A and B was: T: 0. In addition, at this dose sperm count decreased and there was an increase in histopathological lesions (Kunimatsu et al., 2004) . In the Kunimatsu study for the middle dose (10 mg/kg), a significant decrease of prostate weight (ventral and dorso-lateral parts combined) was observed (relative weights g%; T: 0.17 6 0.04 (A), 0.16 6 0.02(B) versus C: 0.24 6 0.04 (A), 0.21 6 0.04 (B), absolute 
F1
A factor to account for extrapolation between species.
• F1 ¼ 5 for extrapolation from rats to humans
• F1 ¼ 12 for extrapolation from mice to humans
• F1 ¼ 2 for extrapolation from dogs to humans
• F1 ¼ 2.5 for extrapolation from rabbits to humans
• F1 ¼ 3 for extrapolation from monkeys to humans
• F1 ¼ 10 for extrapolation from other animals to humans F2 A factor of 10 to account for variability between individuals F3
A variable factor to account for toxicity studies of short-term exposure • F3 ¼ 1 for studies that last at least one half lifetime (1 year for rodents or rabbits; 7 years for cats, dogs, and monkeys).
• F3 ¼ 1 for reproductive studies in which the whole period of organogenesis is covered.
• F3 ¼ 2 for a 6-month study in rodents, or a 3.5-year study in nonrodents.
• F3 ¼ 5 for a 3-month study in rodents, or a 2-year study in nonrodents.
• F3 ¼ 10 for studies of a shorter duration.
F4
A factor that may be applied in cases of severe toxicity, e.g. non-genotoxic carcinogenicity, neurotoxicity or teratogenicity. In studies of reproductive toxicity, the following factors are used:
• F4 ¼ 1 for fetal toxicity associated with maternal toxicity
• F4 ¼ 5 for fetal toxicity without maternal toxicity
• F4 ¼ 5 for a teratogenic effect with maternal toxicity
• F4 ¼ 10 for a teratogenic effect without maternal toxicity
F5
A variable factor that may be applied if the no-effect level was not established • When only an LOEL is available, a factor of up to 10 could be used depending on the severity of the toxicity.
• When a NOAEL is used F5 ¼ 1
• When a LOAEL is used F5 ¼ 10
Weight adjustment
The weight adjustment assumes an arbitrary adult human bw for either sex of 50 kg.
weights (g) T: 0.67 6 0.16 (A), 0.62 6 0.10 (B) versus C: 0.95 6 0.18 (A), 0.81 6 0.14 (B) p < .05). In the Freyberger study, at this dose, histological changes in pituitary and testes were observed and a decrease in weight of the dorsolateral prostate plus seminal vesicle (relative organ weights in mg/100 g: T: 362 6 82 versus C: 470 6 73, p < .05), but not the ventral prostate (relative organ weight in mg/100 g T: 93 6 15 versus C: 123 6 20, p > .05). An effect on epididymis was also observed (relative organ weight (mg/100 g) T: 159 6 20 versus C: 191 6 17, p < .05). In the Kunimatsu study sperm count and morphology, but not sperm motility were affected only at the 100 mg/kg dose. At the 1 mg/ kg dose, which the authors assume to be the NOAEL, only a statistically significant effect on prostate weight (combined) was observed in one of the 2 parallel studies (n ¼ 5 for each) when considering the relative organ weight ( (Kunimatsu et al., 2004) . On the other hand, in the Freyberger study at the 1 mg/kg dose no statistically significant effects were seen (relative organ weight (mg/ 100 g) ventral prostate T: 91 6 12 versus C: 123 6 20, epididymis; T: 183 6 23 versus C: 191 6 17, p > .05). The authors assume that the NOAEL in these two studies is 1 mg/kg/d. In the Ludwig et al. (2011) study young adult male rats (n ¼ 10 per group, 7-week old) were dosed by oral gavage with flutamide for 28 days daily at 0.2, 1, 6, or 30 mg/kg/d. Methylcellulose in sterilized water (0.5% w/v) was used as a vehicle. Initial bw of the rats (in grams) were 263 6 10, 262 6 11, 262 6 12, 262 6 10, 264 6 7 for the control, 0.2, 1, 6 and 30 mg/kg groups, respectively, which were not statistically different. Terminal bws (g) of the rats were 417 6 29, 417 6 29, 418 6 21, 413 6 26, 401 6 26 for the control, 0.2, 1, 6, and 30 mg/kg groups, respectively, which were not statistically different either. Seminal vesicle weight was reduced at the 1, 6, and 30 mg/kg/d doses (absolute organ weight (g): 1.39 6 0.30, 1.29 6 0.32, 1.13 6 0.26*, 0.90 6 0.22*, 0.55 6 0.19*, for the control, 0.2, 1, 6, and 30 mg/kg group, respectively, *p < .05 vs control) while epididymal, prostate weights were reduced (absolute weights/g; epididymis: 0.52 6 0.04, 0.48 6 0.03, 0.48 6 0.07, 0.40 6 0.04* 0.37 6 0.05* for the control, 0.2, 1, 6, and 30 mg/kg, respectively: prostate: 0.44 6 0.12, 0.39 6 0.09, 0.38 6 0.15, 0.29 6 0.07*, 0.21 6 0.05* for the control, 0.2, 1, 6 and 30 mg/kg respectively, *p < .05 vs control), and serum testosterone were increased at the 6 and 30 mg/kg/d, but not at the 1 mg/kg dose. Testis histopathology (Leydig cell [LC] hyperplasia) was seen at 30 mg/kg/d. From this study considering prostate as a sensitive endpoint, 1 mg/kg was considered to be a NOAEL from the standard toxicity endpoints. However, as effect was seen at the 1 mg/kg dose for the seminal vesicles.
In another 28-day toxicity study by Toyoda et al. flutamide was used at doses lower than 1 mg/kg, to a dose as low as 0.25 mg/kg in rats (n ¼ 10 each group, 7-week-old rats, administered flutamide, at 0.25, 4, and 1 mg/kg, once daily by oral gavage for 28 days). Vehicle was 0.5% ethanol in corn oil. Terminal bws (g) were not statistically different (389.9 6 29, 372.8 6 16.7, 374.1 6 19.1, and 373.5 6 17.2 for the 0 (control), 0.25, 1 and 4 mg/kg groups respectively (Toyoda et al., 2000) . In this study male rats receiving 1 and 4 mg/kg dose showed decrease in epididymal weight (absolute organ weight(g); 1 mg/kg: 0.816 6 0.059*, 4 mg/kg: 0.777 6 0.0618* vs C: 0.914 6 0.056; relative organ weights (%) 1 mg/kg: 0.204 60.038*, 4 mg/kg: 0.209 6 0.0021, versus C: 0.236 6 0.025, *p < .05 vs control), while effect on ventral prostate was not seen even at 4 mg/kg (absolute weight/g T: 0.43 6 0.10 vs C: 0.52 6 0.07, relative weight T: 0.117 6 0.029 vs C: 0.135 6 0.021 p > .05). However, dorso lateral prostate and seminal vesicle weight was significantly decreased at 4 mg/kg (absolute weight/g T: 1.47 6 0.26 vs C: 1.80 6 0.23, relative weight T: 0.394 60.07 vs C: 0.461 6 0.055, p < .05). Testosterone and estradiol levels were significantly increased at the 4 mg/kg dose while LH and Follicle Stimulating Hormone (FSH) levels were not affected, nor were sperm motility affected. The authors conclude that the NOAEL is 0.25 mg/kg/d based on the fact that 1 mg/kg epididymis weight was affected. Rouquie et al. (2009) performed the 28-day toxicity study in male rats using doses of 0.04, 0.2, 1, 6, 30, and 150 mg/kg orally by gavage daily with methylcellulose in sterilized water (0.5% w/v) as vehicle (rat 6-week old, n ¼ 6 per group). Terminal bws (g) were not statistically significant between the groups (374.3 6 19.8, 373.5 6 28.8, 371.9 6 35.4, 359.2 6 23.4, 358.2 6 16, 357.0 6 25, 328.0 6 25 for the 0, 0.04, 0.2, 1, 6, 30, and 150 mg/kg groups, respectively). Similar to their previous studies (Friry-Santini et al., 2007) at the 1mg/kg dose no statistical effect was observed on sex organ weight including prostate and epididymis (absolute bw ventral prostate T: 0.39 6 0.13 vs C: 0.38 6 0.03, epididymis: T: 0.39 6 0.08 vs C: 0.46 6 0.07, p > .05). In fact, ventral prostate was not significantly reduced even at the 6 mg/kg dose (absolute weight/g: T: 0.30 6 0.09 vs C: 0.38 6 0.03), a dose where testosterone levels also increased significantly. With respect to histopathology LC hyperplasia was only seen at 6 mg/kg. It was assumed that NOAEL is 1 mg/kg. Andrews et al. (2001) using doses of 0, 1, 10, and 100 mg/kg determined a NOAEL of 1 mg/kg in male rats based on no effects of organ weights at this dose as well as no changes in testosterone, LH, FSH, and prolactin.
In a shorter duration repeat dose toxicity study (20 days, pubertal assay) flutamide was administered at a dose range of 0.15-10 mg/kg (rats 11-weeks old). Flutamide produced significant decreases in weights of the seminal vesicles, epididymis, ventral prostate, and LABC muscles at the 2.5 and 10 mg/kg/d. Serum LH levels, but not testosterone levels, were increased at 10 mg/kg/d, but not at the lower 0.6 mg/kg dose (Yamada et al., 2000) .
Most of the above studies use the same OECD 407 protocol on 28-day toxicity studies and therefore comparisons can be made. However, differences in reporting exist which differentiate the interpretation of the individual studies. The Kunimatsu, Freyberger, and Toyoda studies provide in addition to absolute sex organ weights relative sex organ weights which normalize the weight changes seen on sex organs to bw. In addition, the Freyberger study combines the results from the 2 parallel studies thus having a larger n number (n ¼ 10 from both studies). In the Kunimatsu study, results are presented from individual parallel studies of n ¼ 5 each. In this study it was acknowledged by the authors that the low dose (1 mg/kg/d) results were not reproducible in the separate parallel studies. Results from the combined studies were not numerically presented in the original manuscript, however for the low dose (1 mg/kg/d) it was stated that the combined studies followed the results of the single study that showed statistically significant differences with regard to reduced sex organ weights. The Ludwig study points to a 1 mg/kg NOAEL based on prostate, however a statistically significant effect at this dose was seen on seminal vesicles as well. This study was not primarily conducted to determine conventional toxicity endpoints but rather molecular changes and therefore the results from the conventional changes were supplementary. However, they still point to a possibility of a NOAEL below 1 mg/kg. Additionally, this study has the limitation of presenting only absolute sex organ weights, and not relative. Similarly, the Rouquie study reports the sex organ weight as absolute and not relative. Despite the fact that changes in terminal bws were not different between the studies there exists a possibility that individual bws may have an effect. Finally, the Toyoda study points to a NOAEL of 0.25 mg/kg, where the change was seen both as absolute and relative weights for epididymis.
Based on this literature review it is concluded that the most common reported NOAEL for standard toxicity endpoints given to young rats is 1 mg/kg/d. However the possibility that the NOAEL is slightly below 1 mg/kg/d is evident from the same studies. Since Toyoda et al. reports a NOAEL of 0.25 mg/kg/d this dose is chosen as worst case scenario that will predict a safer PDE from 28-day toxicity studies. The reported NOAELs from the aforementioned 28-day toxicity studies are summarized in Table 2 .
Toxicogenomic Studies
Toxicogenomic studies were coupled to some of the 28-day repeat dose toxicity studies already described to determine whether the NOAEL observed with the conventional toxicity endpoints correlates with changes in testes' gene expression. In the Rouquie et al. (2009) study described in "AR Antagonistic Effect of Flutamide" Section gene expression changes in testis were not seen at 1 mg/kg and below, while changes in gene expression were seen at doses of 6 mg/kg and above. Based on these and consistent with other studies a NOAEL of 1 mg/kg/d was established incorporating toxicogenomic data as well (Rouquie et al., 2009 (2011) 28-day toxicity study (described in "AR Antagonistic Effect of Flutamide" Section) changes in testis gene expression were seen at even the 1 mg/kg dose, while no effect was seen at the 0.2 mg/kg dose. Based on the toxicogenomic studies Ludgwig determined the NOAEL/LOAEL for standard toxicological and toxicogenomic measures to be 0.2/1.0 mg/kg/d, respectively. The Ludwig study could be considered more comprehensive as it used a more thorough gene expression (microarrays) profile than Rouquie et al. study.
In a developmental toxicity study Metzdorff et al. (2007) looked at the effect of flutamide at a dose of 0.77 mg/kg, or 3.86 mg/kg (16 dams per group, dosed by oral gavage daily from GD 7 to 21, and male litter prostate used for mRNA analysis). The mRNA levels of the five androgen-regulated genes PBP C3, ODC, IGF-1, Compl.C3, and TRPM-2 as well as those for the AR were investigated in ventral prostates by real-time RTPCR. No significant effect was observed for flutamide at 0.77 mg/kg.
Similarly, in a study by Maire et al. (2005) flutamide was administered to pregnant rats daily by oral gavage from GD11 to 21 or GD22 at doses of 0, 0.4, 2, or 10 mg/kg/d in methylcellulose as vehicle. F1 male rat offspring were necropsied at 90 days of age, and testes (bilateral descended only) were examined (n ¼ 10 males per group) for flutamide-induced alterations of TGFbligands, TGF-b receptors mRNA, and Smad mRNA. In this study at the lowest dose of 0.4 mg/kg used no effect was seen, with the exception of the phosphorylated c jun.
With regard to toxicogenomic data, the available studies conclude that the NOAELs determined from conventional toxicity endpoints closely follow the changes in gene expression. The toxicogenomic data point to a NOAEL of worst case scenario of 0.2 mg/kg/d. Despite the findings from these studies that gene expression changes could potentially be used for NOAEL determination, conventional endpoints are still considered the gold standard for determining NOAELs, and are unlikely to be replaced by gene expression changes, especially when gene expression changes do not always correlate to protein changes, or even phenotypic changes.
Reproductive/Developmental Toxicity Studies (In Utero Exposure) The effect of flutamide on development of male offspring has also been studied. Numerous studies exist with varying protocols which extend from 16 to 90 days postnatal observations. These studies share commonalities to the extent that flutamide was administered to pregnant rats from GD7 and until at least birth or beyond. Doses used in this study were as low as 0.15 mg/kg/d. Some studies included the whole organogenesis period (GD8-15), and others not. In general the studies are not comparable due to the fact that the endpoint measurements were taken at different times, as indicated in each study.
In a study by Bozec et al. (2004) flutamide was administered to pregnant rats daily by oral gavage from GD10 to 21 or GD22 at doses of 0 (vehicle: methylcellulose), 0.4, 2, or 10 mg/kg/d (n ¼ 15 dams per dose group). F1 male rat offspring were left untreated and necropsied at 90 days of age, and testes (bilateral descended only) were examined (0 mg/kg: 34 animals 5 litters, 0.4 mg/kg: 31 animals 5 litters, 2 mg/kg: 25 animals 5 litters, 10 mg/kg: 15 animals 3 litters). Flutamide induced cryptorchid testes in 33% of the rats only at 10 mg/kg/d, whereas males in the lower dose groups had normal testis descent. Testicular weight (descended and not descended) was not affected by any concentrations. No weights of other sex organs were measured, nor anogenital distance (AGD) or nipple retention (NR) (sensitive endpoints).
Other studies examined more conventional developmental toxicity endpoints. In a study by Hass et al. (2007) flutamide was dosed by oral gavage daily from GD7 to 21 and then from postnatal day (PND) 1 to 16, when the animals were necropsied. The doses used were 0.5, 1, 2, 4, 8, or 15 mg/kg/d, (n ¼ 8 dams per group, distributed with similar bw), and examined the reproductive development of the male offspring up to 16 days of age. Flutamide did not alter maternal bw gain. The authors examined AGD and female-like NR as critical endpoints. Dose-related Yamada et al. (2000) 0.6 mg/kg/d -Sex organs effects were noted in all the treated groups with NR being the most sensitive endpoint followed by neonatal AGD in the male offspring. The AGD was not significantly different from controls. According to the authors, 0.5 mg/kg/d was a lowest observed effect level (LOEL) (based upon NR in male rat offspring), but a NOEL was not established. Despite the reporting of the LOEL, the study does not examine effect of flutamide on organ weights, nor does it report the weight of the offsprings. Despite the fact that the authors chose doses that would not affect the bw, and thus not complicate examination of AGD and NR, the weights are not reported. The study does not give sufficient details, nor does it give detailed results to allow for proper evaluation. In a similar study by Metzdorff et al. (2007) flutamide was administered from GD7 through 21 by oral gavage daily (n ¼ 8 dams per group, approximately 200 g), and then from PND1-16 daily by oral gavage, and pups examined at day 16 (doses 0.5, 1.0, 2.0, 4.0, 8.0, and 15 mg/kg dissolved in corn oil). One to four males per litter were used for organ weight, with litter size ranging from 4 to 10. The maternal bw gain from GD7 to PND1, litter size birth weight of male and female offsprings, sex ratio in litters, pub weight were similar to controls. No changes in bw (g) of treated male pups compared with control were observed as assessed at PND16 (34.1 6 1.3, 32.7 6 0.6, 34.6 6 1.1, 36.4 6 0.6, 35.6 6 1.3, 34.8 6 1.1 for the 0.5, 1, 2, 4, 8, and 16 mg/kg groups, respectively vs 34.7 6 1.1 control group; p > .05). Flutamide induced significant changes in ventral prostate and seminal vesicles weight at the lowest dose used (0.5 mg/kg) (ventral prostate weight (mg) T: 13.8 6 0.8 vs C: 16.5 6 0.6 p < .05, seminal vesicle: T: 9.9 6 0.3 vs C: 12.0 6 0.9 p < .05). Testis weight was not affected at the dose of 1 mg/kg (T: 62.6 61.2 mg vs C: 66.4 61.2 mg) whereas epididymides weight was significantly decreased at the 1 mg/kg dose (T: 22.7 6 1.5 mg vs C: 27.0 6 1.1 mg, p < .05), but not at the 2 and 4 mg/kg dose: 26.7 6 1.6 mg, 24.1 6 1.8 mg, respectively versus C: 27.0 6 1.1. In a separate study a dose of 0.77 mg/kg did not affect these weights (ventral prostate/mg: T: 15.5 6 0.5 vs C: 17.1 6 0.9, seminal vesicle T: 8.3 6 1.0 vs C: 11.0 6 0.9, p > .05), but affected epididymides weight (mg) (T: 22.4 6 1.1 vs C: 25.3 6 0.8, p < .05). In addition, at a dose of 0.77 or 3.86 mg/kg no histopathological changes were observed in prostate, epididymides and seminal vesicles. Conclusively, since an effect was seen at 0.5 mg/kg on prostate, this level dose was a LOAEL in agreement with the Hass et al. study. However, in this study AGD was not examined. The fact that at the lowest dose used there was adverse effect a NOAEL could not be established, however it is a fairly comprehensive study with sound conclusions, despite the fact that relative organ weights were not reported. Miyata et al. (2002) administered flutamide by gavage in 0.5% carboxymethylcellulose (0, 0.15, 0.6, 2.5, 10, 100 mg/kg/d, n ¼ 4-6 per group) to pregnant rats from GD14 to PND3 daily, and examined the postnatal development of the male offspring after birth up to 60 days of age. Fertility, pup weight, AGD, NR, testis descent, and urogenital malformations were determined. Some animals were necropsied at 4 days of age while the rest were necropsied at 60 days of age, organ weights taken, and hormonal and histopathological evaluations conducted. Number of pups and proportion of male/female were not statistically different from the control group, while at PND60 the weight of offsprings of the 100 mg/kg group was significantly lower compared with the rest. AGD was decreased at 2.5 mg/kg and above (measured at PND21 in mm 2.5 mg/kg: 11.50 6 0.941 vs 12.75 6 0.934 control, p < .001, measured at PND0: 10mg/kg: 1.80 6 0.286 versus 2.57 6 0.293 control p < .01). At the 10 mg/kg dose female-like retained nipples, vaginal pouch, penis malformations, undescended testes, and decreased organ weights (prostate, LABC muscle) were observed (relative organ weight (%) LABC; T: 0.14 6 0.044 vs C: 0.24 6 0.037, ventral prostate; T: 0.06 6 0.015 vs C: 0.11 6 0.012, dorso lateral prostate: T: 0.10 6 0.017 vs C: 0.14 6 0.023, p < .01 for all). Histopathological defects included atrophy and inflammatory alterations in several reproductive tract tissues and were observed at 10 mg/kg and above. The levels of FSH, LH or testosterone were not affected at the low doses. The authors concluded that the most sensitive measure was AGD, whereby reduction was observed at 2.5 mg/kg at PND21 and that 0.6 mg/ kg/d was a clear NOEL. However, the AGD at PND0 was decreased at 10 mg/kg making the 2.5 mg/kg dose a possible NOEL. In this study administration of flutamide was not given for the whole period of organogenesis which starts at GD8 in rats. This obviously has implications on the true effect of flutamide, which in this study may have been underestimated. Whether administration of flutamide for additional 6 days during organogenesis would have had a significant effect in this study is not known. However, the absence of this may result in overestimation of the PDE because a modifying factor of 10 needs to be applied, instead of 1 used for full organogenesis in which case may over estimate a PDE calculated based on NOELs from this study.
In a study by Yamasaki et al. (2005) pregnant rats (16 weeks of age) were dosed daily orally with flutamide dissolved in oil (vehicle) at 0.4, 2, or 10 mg/kg/d from GD6 to PND20 (12-16 dams per dose group), and the effects of flutamide exposure on male offspring were examined 10 weeks after birth (n ¼ 11-14 per group). In addition, flutamide treatment was continued after weaning for one half of the males so that the effects of flutamide could be compared with the offspring that were not treated after weaning. Litter size was not statistically significant different between the groups (13.1 6 1.7, 13.7 6 2.4, 12.5 6 2.8, and 11.4 6 4.6 for the 1, 0.4, 2, and 10 mg/kg dose groups, respectively). Offspring male:female ratio were not statistically different either and were 83/101, 75/89, 96/91, and 67/67 for the 0, 0.4, 2, and 10 mg/kg group, respectively).
At the 2 and 10 mg/kg dose a reduced AGD, and small testis were observed when examined at PND4, but there was no effect on NR. At these doses the age of preputial separation (PPS-puberty in males) was delayed with continuous exposure. Continuous exposure to flutamide also caused increases in serum LH and testosterone (only at 10 mg/kg/d), and continuous treatment was more effective in reducing androgen-dependent tissue weights than was flutamide treatment only during gestation and lactation. For animals treated continuously after weaning a dose of 2 mg/kg showed statistically significant reduction in relative organ weight (mg/100 g bw, epididymis; T: 166.8 6 15.5 vs C: 193.1 6 22.6, seminal vesicle; T: 180.4 6 44.9 vs C: 247.4 6 49.1, ventral prostate; T: 65.6 613.5 vs C: 90.1 6 24.0, glans penis; T: 20.7 6 2.6 vs T: 25.3 6 2.8, p < 0.05). No statistical effect was seen at the 0.4 mg/kg dose (epididymis; T: 197 6 21.2 vs C: 193.1 622.6, seminal vesicle; T: 225.3 6 59.5 vs C: 247.4 6 49.1, ventral prostate; T: 79.6 623.2 vs C: 90.1 6 24.0, and glans penis; T: 25.5 6 2.1 vs T: 25.3 6 2.8, p > .05). For animals left untreated the dose that caused an effect was 10 mg/kg. (Yamasaki et al., 2005) .
In this study AGD is the most sensitive endpoint when measured at PND4, and a NOAEL of 0.4 mg/kg is considered based on the fact that statistically significant effect was observed at the 2 mg/kg dose. The weights of the offspring were reported to be normal. With regard to the sex organ weights, the study considered two approaches. In one approach offspring were treated continuously for 10 weeks with flutamide and a second approach groups were left untreated. As it can be seen from the above results, statistically significant effect for continuous treatment is seen at the 2 mg/kg dose, while for the discontinues treatment statistically significant effect on organ weights is seen at the 10 mg/kg dose. In this regard, for continuous treatment the NOAEL is 0.4 mg/kg and for discontinuous the 2 mg/kg dose. Obviously this difference is perplexing as in the case of discontinuous one can argue that the effects were partially reversed, nevertheless developmental changes at the 10 mg/kg dose were visible at least 10 weeks after. In the case of continues the effects could be due to the treatment for 10 weeks and not due to developmental effects. Therefore, these questions the NOAEL for 0.4 mg/kg derived from the continuous treatment, and makes it less reliable. The NOAEL for continuous treatment after puberty is assumed to be 0.4 mg/kg based on organ weight reduction. The authors suggest that a NOAEL of 2 mg/kg exists; however, a safer number will be the next dose level (0.4 mg/kg) since an effect was seen in the continuous exposure.
In a study by McIntyre et al. (2001) pregnant rats (8-10 weeks of age) were dosed by oral gavage daily with 0, 6.25, 12.5, 25, or 50 mg flutamide/kg/d dissolved in corn oil (vehicle) (n ¼ 11-12 dams per group) from GD12 to 21 and AGD, areola/NR, cryptorchidism, reproductive organ weights, and malformation incidence were examined on male offspring. In utero flutamide exposure statistically caused a decrease in the AGD at birth, increased female-like and induced reproductive NR in infant male rats, and induced reproductive tract malformations including undescended testes, hypospadias, prostate agenesis, and epididymal agenesis, and decreased the weights of the seminal vesicles, LABC muscles, testes, and epididymis in a dose-dependent manner. This study however uses a much higher concentration than the others even for the lowest dose. The effects observed are not unexpected for the dose used. In utero flutamide exposure did not alter sex ratio or male pup weight at PND21. Furthermore dams treated with 50 mg/kg/d from GD12 to 21 showed a significant decrease (8%) in bw compared with control.
From the above studies it is concluded that when developmental effects of flutamide are concerned AGD is the most sensitive endpoint at birth, while when considering additional effects of flutamide given to rats after birth, seminal vesicle, ventral prostate and epididymis weights are the most sensitive endpoints.
The developmental toxicity studies point to a NOAEL of 0.4 mg/kg when AGD is considered to be the most sensitive endpoint (full organogenesis). The NOAELS or LOAELs from developmental studies are summarized in Table 3 .
However, as discussed these studies are variable and direct comparison between them cannot be made. Despite this the 0.4 mg/kg is a NOAEL considering AGD as sensitive endpoint. It is acknowledged that in the absence of bws, this may be misleading since AGD is depended on bw (Gallavan et al., 1999) . Since the authors state that bws were not altered by treatments it can be assumed, but not proved, that bw will not change the result derived from this end point. However, this should be viewed with caution. From these studies the LOAEL of 0.5 mg/kg seems to be the most reliable to be used for PDE calculation based on the Mertzdorff study, and considering sex organ weights as sensitive endpoints.
Toxicity of Flutamide in Female Rats
Most of the toxicity studies conducted test the effect of flutamide on male rats, a logical consequence of the use of flutamide. However, toxicity of flutamide to female rats is also important for the purpose of this report, considering that any residual of flutamide in tablets may be ingested by females as well. Kim et al. (2002) studied of the effect of flutamide in female rats in a 20-day pubertal assay. Rats were treated with flutamide dissolved in corn oil at doses ranging from 1 to 25 mg/kg/d at age 21 days for 20 days daily by oral gavage (n ¼ 10 per group). Treatment did not have an effect on bws (initial bws in g 52.50 6 1.13, 50.50 6 0.093, 50.80 6 0.78, 51 6 097 for 0, 1, 5, and 25 mg/kg groups respectively, terminal bw 156.70 6 1.81, 157.40 6 3.76, 164.80 6 2.53, 159.70 6 1.95 for the 0, 1, 5, and 25 mg/kg groups, respectively). At the highest dose flutamide decreased ovary weight (absolute weight/mg C: 54.77 6 3.04, T: 41.73 6 2.10 p < 0.005), while uterus was unaffected (absolute weight/mg C: 0.28 6 0.02 T: 0.23 6 0.001 p > .05). Flutamide also seemed to have affected pituitary and adrenal glands at the lowest dose of 1 mg/kg (adrenal weight/mg C: 42.43 6 2.00 vs T: 35.86 6 1.51, pituitary weight/mg C: 10.30 6 0.56 vs T: 8.10 6 0.34 p < 0.05); however, this is not fully supported as higher doses had no effect. The age at vaginal opening (VO) was decreased only at the 25 mg/kg dose (ie, accelerated VO), while the oestrous cycle was increased only at the highest dose (Kim et al., 2002) .
In the developmental toxicity study by McIntyre et al. (2001) described above, it was noted that the AGD was not altered in the female offspring (lowest dose 6.25 mg/kg) when examined alongside the male offspring. Considering that the dose is high (6.25 mg/kg) this indicates no effect on females at lower doses. Flutamide did not affect oestrous cycles or interfered with the mating behavior of male and female rats when the drug was administered at 25 and 75 mg/kg/d prior to mating (Merck, 2011) In a study by Toyoda et al. (2000) , female rats 7 weeks of age, n ¼ 10 per group, were administered flutamide dissolved in 0.5% ethanol in corn oil, by oral gavage daily for 32 days at doses of 0.25, 1, and 4 mg/kg. The 4 mg/kg dose caused prolongation of oestrous cycle for 40% of the animals in this group (from 4 to 5 days), while there were no effects on testosterone, estradiol, FSH or LH even at the 4 mg/kg dose. On the other hand, Andrews et al. (2001) in a 28-day toxicity study incorporating female rats and administering daily flutamide by gavage doses of 1, 10, and 100 mg/kg/d found that none of the doses caused a change in the oestrus cycle. In fact, they concluded that the NOAEL for female rats was 10 mg/kg.
In the Metzdorff et al. (2007) study no clinical signs of maternal toxicity was observed for flutamide given at doses 0.5-15 mg/kg. The maternal bw gain from GD7 to PND1, pregnancy length, litter size, birth weight of male and female offspring, sex ratio in the litters, and pup weight gain and survival were unaltered in all groups when compared with controls as previously described.
Based on these it is concluded that flutamide is unlikely to cause developmental abnormalities in female offspring considering that the AGD, as a most sensitive endpoint, was not affected. The other studies also point to no effects at low doses of flutamide (>1-6.25 mg/kg).
Even though there is limited information on female toxicity compared with male, the effect of flutamide on females should be less than in males due to the mode of action on ARs. This in fact is supported by the Andrews study where the NOAEL is 10-fold higher in female compared with male (Andrews et al., 2001) .
Genotoxicity/Carcinogenicity/Mutagenicity Strong literature evidence for the genotoxicity and carcinogenicity potential of flutamide is lacking. There are very few reports available and the doses used are in much excess of the human dose. The information presented below mostly comes from product monographs, and some articles.
Genotoxicity. Flutamide genotoxicity was evaluated in intact rat and in primary cultures of human hepatocytes. In rats given a single oral dose of 500 mg/kg flutamide, fragmentation, and repair of liver DNA were absent, and no increase was observed in the frequency of micronucleated hepatocytes. When given as an initiating agent at the dose of 500 mg/kg/wk for 6 successive weeks, c-glutamyltraspeptidase-positive foci were detected only in 3 of 10 rats. In addition, there was no evidence of a promoting effect on the development of aberrant crypt foci in rats given 100 mg/kg flutamide on alternate days for 8 successive weeks.
In primary cultures of human hepatocytes DNA fragmentation and DNA repair synthesis were absent after a 20 h exposure to flutamide concentrations up to 56 mM. Taken together these data suggest that flutamide is not genotoxic (Martelli et al., 2000) .
Carcinogenicity. Daily administration of flutamide to rats for 52 weeks at doses of 30, 90, or 180 mg/kg/d (approximately 3, 8, or 17 times the human dose), produced testicular interstitial cell adenomas at all doses (Merck, 2011) , and flutamide was carcinogenic in rats at doses equivalent to >3 times the human dose (BC Cancer Agency, 2014) . In it worth noting that susceptibility of rats to testicular cancer is different from that of humans. Physiological differences between the rat and the human LCs, including higher number of LC receptors in rats versus humans makes the rats more susceptible to cancers than humans, especially to Leydig cell tumors (LCTs) (Cook et al., 1999) . In fact, endocrine substances including flutamide, induced LCTs, while finasteride can induce LC hyperplasia. For this reason flutamide is not considered to be a carcinogen.
Furthermore, the U.S. Pharmacopoeia safety data sheet for flutamide states that flutamide is suspected of causing cancer, and is not considered to be a carcinogen by International Agency For Research On Cancer, National toxicology Program, or Occupational Safety and Health Administration (USP, 2014 Revision).
In conclusion, flutamide is not carcinogenic, and carcinogenicity is observed rarely and only in very high doses, higher than the therapeutic doses in humans. Therefore, carcinogenicity is not a hazard according to guidelines.
Mutagenicity. Flutamide is not mutagenic as it did not demonstrate DNA modifying activity in the Ames Salmonella/microsome mutagenesis Assay (BC Cancer, 2014; Merck, 2011) 
PDE DETERMINATION
Based on this analysis and taking into consideration the NOAELs and LOAELs reported, the most sensitive end points and the species used, the PDE is determined according to the guidelines as described in the Materials and Methods section (EMA/CHMP/CVPM/SWP/169430/2012 Guideline on "Setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities" and VICH GL 18 guideline "VICH GL 18 residual solvents in new veterinary medicinal products, active substances and excipients" (CVPM, 2010; EMEA, 2014) . Taking into consideration the above studies, a NOAEL of 0.25 mg/kg was chosen as the most appropriate from the 28-day toxicity studies and a LOAEL of 0.5 mg/kg from a reproductive/developmental toxicity studies. In both cases sensitive end points were sex organ weights. Accordingly, PDEs from these two were calculated.
PDE Based on 28-Day Toxicity Studies
For the PDE determination, based on 28-day toxicity studies, F1-5 values were F1 ¼ 5, F2 ¼ 10, F3 ¼ 10, F4 ¼ 1, F5 ¼ 1 as explained in Table 4 . The PDE based on 28-day toxicity studies was calculated to be 0.025 mg/d. This was based on the NOAEL of 0.25 mg/ kg reported and considering epididymis as the critical effect. The other studies reviewed pointed to a NOAEL of equal or less than 1 mg/kg.
PDE Based on Developmental Studies
The PDE is determined based on the LOAEL of 0.5 mg/kg. For this calculation F1, F2, and F4 values were equal to 5, 10 and 1, repsecitvely. For F3 a value of 1 was assigned since treatment was given during the full organogenesis period, and F5 was assigned a value of 10 since a LOAEL was used instead of a NOAEL. The PDE based on developmental studies were found to be 0.05 mg/d (Table 4) .
DISCUSSION
The PDE for flutamide was calculated based on the available literature peer reviewed data, and using the EMEA guidelines. The available published flutamide toxicity studies focus mainly on 
2001
; Metzdorff et al., 2007; Miyata et al., 2002; Yamasaki et al., 2005) , (2) toxicity studies, administering the drug to young or adult rats (5-10 weeks of age) (Andrews et al., 2001; Freyberger et al., 2003; Kunimatsu et al., 2004; Ludwig et al., 2011; Rouquie et al., 2009; Toyoda et al., 2000) , or (3) toxicogenomic studies looking at the effects of flutamide on alterations in gene expression with preference on gene expression in testis (Ludwig et al., 2011; Rouquie et al., 2009) . In all studies flutamide was administered by oral gavage, some studies determine NOAEL levels, and mostly examine the effects on male rats. Comparatively, little information is given about toxicity in female rats as flutamide is primarily indicated for use in male patients. However, for the purpose of this report and its implications, the effects on females was considered when available since the carryover of flutamide (drug A) in any drug that follows flutamide production (drug B) in a pharmaceutical production facility may affect female who ingest drug A.
From all the studies reviewed, the most common toxicity endpoints identified (critical effects/sensitive endpoints) from the reproductive developmental toxicity studies are AGD NR, and sometimes testis descend, along with sex organ weights (ventral prostate, sceminal vescicles, epididymis, etc) . Although some studies for developmental toxicity also look at urogenital malformations, these have not been proved to be the most sensitive endpoints.
Sensitive endpoints in postweaning toxicity studies are sex organ weight, and specifically change in weight of the ventral prostate, seminal vesicles and epididymis. Although some studies look at more than these sensitive points, it has been determined that these are the most sensitive endpoints when looking at the effects of androgens and androgen blockers. Changes in hormones such as Testosterone and LH are not considered sensitive endpoints, but are usually measured and required by OECD toxicity protocol for EDCs. In fact, the proof of a compound to be antiandrogen comes from its effect on a number of parameters arising primarily from the Hershberger assay or from pubertal male assays (Borgert et al., 2014) .
Even though common toxicity endpoints (reduced AGD, retained nipples, effects on accessory sex gland weight, hypospadias, epididymal agenesis) are believed to be elicited by interference at the level of the AR, they may display a wide variety of effective dose levels to produce statistically significant changes. Some of these changes do not exhibit an obvious threshold in the range of the experimental dose levels. This gave rise to the idea of low dose or nonmonotonic dose responses (NMDRs) curves whereby chemicals that follow NMDRs could yield NOAELs at least an order of magnitude too high in studies not conducted appropriately (Vandenberg et al., 2012) .
The concept of NMDRs curves or low dose has recently received attention especially in the case of EDC. In this regard, in NMDRs, curves are not linear but are nonmonotonic (U shaped or other). The implication is that if the dose range used in toxicity studies is not order of magnitudes apart, a nonmonotonic response may be missed (Vandenberg et al., 2012) . For EDCs this is important because hormones have biological effects at very low doses, and these doses are usually much lower than what are used in toxicology. Therefore, a possibility exists that a NOAEL is not the safe dose if a drug shows NMDRs, but the safe dose could be much lower. In the absence of appropriate experimental detail and dose ranges this may be missed.
Despite the fact that NMDRs may exist for a variety of chemicals they are likely to be observed mostly in vitro rather than in vivo. At the same time a safe assessment of NMDR requires stepwise approach with criteria and experiments well controlled and free of experimental errors to ascertain the true presence of NMDRs (Beausoleil et al., 2016; Lagarde et al., 2015) . With regard to estrogen and androgens's NMDRs a complete analysis of available studies failed to verify the full significance of NMDRs in vivo, while there is not sufficient evidence of NMDRs having adverse effects below NOAELs identified by standard testing strategies. Despite this, evidence for flutamide exhibiting NMDR was sought in order to perform an exhaustive analysis of the behavior of the antiandrogen.
Flutamide does not seem to show NMDR as in all studies described the doses used were from 0.04 to 150 or even 200 mg/ kg in which case if a NMDR was to be seen with these dose ranges it would be obvious. Considering that the lowest NOAEL was 0.25 mg/kg and the more common 1 mg/kg, the lowest 0.04 mg/kg dose used represents an almost 5-fold lower dose, in which case if a NMDR was present it would probably be visible at that low dose. Irrespective of these, two recent studies prove that flutamide does not show NMDR, as in these studies doses as low as 0.00025 mg/kg of flutamide were used and a NMDR was not observed (Fussell et al., 2015; Sarrabay et al., 2015) . To this end, NMDR does not seem to be of concern in this report as there is little evidence for the NMDR especially for antiandrogens. This finding is consistent with the observed data indicating that NMDR has not been able to identify adverse effects below the NOAEL determined from standard methods for compounds with androgenic or estrogenic activity.
The PDE determined from different studies ranges from 0.025 mg/d as determined from the 28-day toxicity studies, to 0.05 mg/d determined from the developmental toxicity studies. The selection of a NOAEL of 0.25 mg/kg comes from a 28-day toxicity study and the critical effect was epididymis. The LOAEL of 0.5 mg/kg comes from the developmental study where the critical effect was ventral prostate and seminal vesicles. The latter represent a more relevant critical endpoint of antiandrogenic activity, however epididymis is also considered an endpoint/marker despite the fact that is not considered tier 1 marker (Borgert et al., 2014) . In this regard the calculated PDE of 0.025 mg/d may be slightly overestimated but it cannot be neglected. However, the deviation between the 2 or from other studies is not considered significant. Even though most investigators state that the NOAEL is 1 mg/kg/d (PDE ¼ 0.1 mg/d) as determined from 28-day toxicity studies, we could not exclude the other studies showing lower NOAELs for additional safety, and following always the worst scenario for calculating PDE. In addition, males are more sensitive to potential toxicity than females, a condition that has been proved here since the NOAEL for females were found to be 10-fold higher than those for male rats.
As indicated by the PDE formula a number of factors are involved in calculating PDEs which some account for the difference in species, whether a NOAEL or a LOAEL is used, etc. Obviously there are a lot of uncertainties around PDE determination from these factors. Additional uncertainties may arise from difference in species sensitivities by each chemical which may not be fully taken into account by the safety factors applied. The PDE was calculated based on the EMEA directive. It is a fact however that rat and human sensitivity to antiandrogens is different. In fact according to Borgert et al. (2012) for antiandrogens a 1-to 5-fold difference should be applied to account for the observed lower sensitivity of humans compared with rats. This means that the PDE calculated in this report taking into consideration the guidelines of the directive and the modifying factors may be an overestimate. In the absence of a complete dataset for flutamide as presented for other androgen antagonists in Borgert et al. a specific fold correction cannot be made. It is reasonable to assume, though, that a difference may exist in this case as well.
Furthermore, the PDE is based on a weight of human of 50 kg, a rather low average weight (compared with 60 or 70 kg normally used) and was used for additional safety as indicated by the EMEA directive. Therefore, the PDE calculated for flutamide, considering differences in species sensitivities, and weight differences, is likely to be on the safest side in the absence of any other information to indicate different NOAELs than the ones used. Therefore, the calculated PDE is not an absolute number, but represents a reference. For the case of flutamide, this PDE is likely to represent the safest estimate.
In conclusion, the safety of flutamide carry over to the next pharmaceutical batch in tablets will depend on the batch size and the degree of carryover of flutamide. Depending on the cleaning validation data a carryover may be estimated. If the estimated carryover (per tablet per daily dose) is less than the PDE, safety to humans is assured. If the carry over (per tablet per daily dose) is higher than the PDE there exists potential toxicity to humans and especially males taking a drug everyday for lifetime that contains residual flutamide that is in excess of 0.025 mg.
